Influence of Molecular Structure on the In Vivo Performance of Flexible Rod Polyrotaxanes

Polyrotaxanes, a family of rod-shaped nanomaterials comprised of noncovalent polymer/macrocycle assemblies, are being used in a growing number of materials and biomedical applications. Their physiochemical properties can vary widely as a function of composition, potentially leading to different in vivo performance outcomes. We sought to characterize the pharmacokinetic profiles, toxicities, and protein corona compositions of 2-hydroxypropyl-β-cyclodextrin polyrotaxanes as a function of variations in macrocycle threading efficiency, molecular weight, and triblock copolymer core structure. We show that polyrotaxane fate in vivo is governed by the structure and dynamics of their rodlike morphologies, such that highly threaded polyrotaxanes are long circulating and deposit in the liver, whereas lung deposition and rapid clearance is observed for species bearing lower 2-hydroxypropyl-β-cyclodextrin threading percentages. Architecture differences also promote recruitment of different serum protein classes and proportions; however, physiochemical differences have little or no influence on their toxicity. These findings provide important structural insights for guiding the development of polyrotaxanes as scaffolds for biomedical applications.

[1]  Zhuxian Zhou,et al.  Gd3+-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-β-cyclodextrin/Pluronic Polyrotaxane as a Long Circulating High Relaxivity MRI Contrast Agent. , 2015, ACS applied materials & interfaces.

[2]  Shuling Yu,et al.  One-pot synthesis of water-soluble, β-cyclodextrin-based polyrotaxanes in a homogeneous water system and its use in bio-applications. , 2015, Journal of materials chemistry. B.

[3]  E. Conway,et al.  Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. , 2014, ACS nano.

[4]  H. Merlitz,et al.  Grafted Polyrotaxanes: Scaling Theory and Molecular Dynamics Simulations , 2014 .

[5]  Korin E. Wheeler,et al.  Silver nanoparticle protein corona composition compared across engineered particle properties and environmentally relevant reaction conditions , 2014 .

[6]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[7]  D. Thompson,et al.  Synthesis of 2-hydroxypropyl-β-cyclodextrin/pluronic-based polyrotaxanes via heterogeneous reaction as potential Niemann-Pick type C therapeutics. , 2013, Biomacromolecules.

[8]  Chunlei Zhu,et al.  Conjugated polymer nanoparticles: preparation, properties, functionalization and biological applications. , 2013, Chemical Society reviews.

[9]  D. Thompson,et al.  Synthesis, characterization, and evaluation of pluronic-based β-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick type C fibroblasts. , 2013, Biochemistry.

[10]  Giulio Caracciolo,et al.  Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[11]  Kyle J. Wright,et al.  Cationic α-cyclodextrin:poly(ethylene glycol) polyrotaxanes for siRNA delivery. , 2013, Molecular pharmaceutics.

[12]  Nicolas Bertrand,et al.  The journey of a drug-carrier in the body: an anatomo-physiological perspective. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[14]  Nicholas Melosh,et al.  Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. , 2012, Nano letters.

[15]  Stefan Tenzer,et al.  Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.

[16]  Taeghwan Hyeon,et al.  Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. , 2011, Accounts of chemical research.

[17]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[18]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[19]  J. Repa,et al.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid , 2010, Journal of Lipid Research.

[20]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[21]  Tohru Mizushima,et al.  Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles , 2009, Pharmaceutical Research.

[22]  M Laird Forrest,et al.  Effects of nanomaterial physicochemical properties on in vivo toxicity. , 2009, Advanced drug delivery reviews.

[23]  Haifang Wang,et al.  Long-term accumulation and low toxicity of single-walled carbon nanotubes in intravenously exposed mice. , 2008, Toxicology letters.

[24]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[25]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[26]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[27]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[28]  W. Malorni,et al.  The microenvironment can shift erythrocytes from a friendly to a harmful behavior: pathogenetic implications for vascular diseases. , 2007, Cardiovascular research.

[29]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[30]  Aaron M Mohs,et al.  Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential , 2007, Expert opinion on drug delivery.

[31]  D. Thompson,et al.  Synthesis, characterization, and pH-triggered dethreading of alpha-cyclodextrin-poly(ethylene glycol) polyrotaxanes bearing cleavable endcaps. , 2006, Biomacromolecules.

[32]  N. Yui,et al.  Surface modification of polyurethane using sulfonated PEG crafted polyrotaxane for improved biocompatibility , 2006 .

[33]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[34]  S. Gould,et al.  2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review , 2005 .

[35]  Olivier Barbier,et al.  Effect of Heavy Metals on, and Handling by, the Kidney , 2005, Nephron Physiology.

[36]  N. Yui,et al.  Anticoagulant supramolecular-structured polymers: Synthesis and anti coagulant activity of taurine-conjugated carboxyethylester-polyrotaxanes , 2005 .

[37]  A. Kabanov,et al.  Pluronic block copolymers: novel functional molecules for gene therapy. , 2002, Advanced drug delivery reviews.

[38]  J. Hamilton,et al.  Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.

[39]  N. Yui,et al.  Effect of biodegradable polyrotaxanes on platelet activation. , 1998, Bioconjugate chemistry.

[40]  N. Yui,et al.  Thermally switchable polyrotaxane as a model of stimuli‐responsive supramolecules for nano‐scale devices , 1996 .

[41]  N. Yui,et al.  Synthesis of a biodegradable polymeric supramolecular assembly for drug delivery , 1995 .

[42]  Akira Harada,et al.  The molecular necklace: a rotaxane containing many threaded α-cyclodextrins , 1992, Nature.

[43]  H. Frijlink,et al.  The Pharmacokinetics of β-Cyclodextrin and Hydroxypropyl-β-cyclodextrin in the Rat , 1990, Pharmaceutical Research.

[44]  A. Zimmer,et al.  Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  Kenneth A. Dawson,et al.  Nanobiotechnology: nanoparticle coronas take shape. , 2011, Nature nanotechnology.

[46]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.